Join our Solid Cancer Observatory

Using real-world data, the Solid Cancer Observatory maps treatment pathways and outcomes across solid cancers with tailored endpoints for each tumor type in prostate, lung, colorectal and breast to uncover opportunities to improve care, reduce variation, and better align treatments with patient needs.

Gain Unique International Pan-European Insights

The Solid Cancer Observatory fills a critical gap in oncology research by connecting real-world data sources that are often siloed — from clinical records to pharmaceutical use and biomarker testing. Where traditional cancer registries tend to focus on a single aspect of care or a limited patient population, the Observatory enables a broader, more integrated view across tumor types and healthcare systems. This approach uncovers structural differences in care delivery, supports cross-country comparisons, and brings visibility to treatment decisions that are shaped by both diagnostic insights and local practice patterns.

Improving Oncology Care and Operational Insight

The Solid Cancer Observatory offers hospitals a dual lens on cancer care, combining insights into both medication use and hospital-based interventions such as surgeries and radiotherapy. This integrated view supports more informed clinical decision-making and allows hospitals to better understand the resource implications of different treatment strategies. By retrospectively analysing real-world treatment pathways — including drug combinations, outcomes, and variation in surgical volumes — hospitals can benchmark their performance, evaluate care efficiency, and explore opportunities to optimise both outcomes and resource allocation. With a focus on major tumor types like prostate cancer, the Observatory also provides a platform for research and publication, helping hospitals contribute to the broader oncology knowledge base.

Unlocking Deeper Real-World Evidence

The Solid Cancer Observatory provides a dynamic, longitudinal view of real-world oncology care. It enables detailed insights into how therapies are used in practice — including treatment line, sequencing, and combination patterns — as well as the adoption of biomarker testing and its role in clinical decision-making. Sponsors gain visibility into both the uptake and real-world performance of drugs across hospitals and patient populations. Unlike static datasets, the Observatory continuously evolves, allowing for retrospective analyses and ongoing exploration of treatment pathways and outcomes over time. All insights are fully anonymised and aggregated, supporting high-quality evidence generation while safeguarding patient privacy.

Simple, Free Participation with Immediate Benefits

Hospitals can join the Solid Cancer Observatory at no cost and easily integrate into their existing data systems. Participation requires minimal effort, allowing hospitals to contribute valuable real-world data while gaining direct access to actionable insights into their own cancer care pathways. By participating, hospitals can evaluate their treatment practices, optimise resource use, and compare outcomes against broader benchmarks. Every participating hospital not only benefits from these insights but also contributes to closing critical knowledge gaps in oncology care, helping to shape the future of cancer treatment and healthcare delivery.

analytics_200dp_033BFC_FILL0_wght400_GRAD0_opsz48

Data granularity

The level of detail LOGEX has access to is unique, allowing exceptional visibility into patient pathways. E.g.:

Patient pathway mapping
Lines of treatment
Combinations of drugs and indication split
Filter on specific patient groups

Data access & recency

We re-use existing, up-to-date data. This is processed at a regular frequency with an exceptionally low lag time and reporting frequency of ~1-3 months*.

Longitudinal insights

Our continued access to data from the same hospitals since 2020 allows for a longitudinal view, supporting multi-year analysis and benchmarking

Scalability

The observatory setup allows for quick expansion into related disease areas under the same contracts.

With our extensive network of hospitals across Europe, expanding into other countries is highly feasible.

Experience

LOGEX has over 10 years of experience working with 700+ healthcare providers across the EU.

We are experts in extracting, delivering, validating and analysing healthcare datasets in close collaboration with HCPs.

Security by design

NEN7510 and ISO27001 certified, full compliance with GDPR.

FG and security officers, authorisation levels, two-factor authentication, informed / explicit consent.

Frequently Asked Questions

The legal basis for processing data in our projects is provided by GDPR article 9.2(h), which covers projects designed to improve "the management of health or social care systems and services."

The hospital is the data controller, while LOGEX acts as the data processor, ensuring data is handled according to the legal and ethical guidelines.

Ethical approval might be necessary in specific cases and is dependent on local guidance and regulations. The focus of the observatory is to improve healthcare and outcomes for participating hospitals, which means ethical approval is not required in certain countries or specific situations.

Hospitals remain the owners of their data at all times. Only anonymous population data may be shared with third parties, and LOGEX strictly follows local regulations regarding cross-border data transfers.

The Solid Cancer Observatory focuses on cancers that involve solid tumors, such as prostate, colorectal (colon), lung, and breast cancer. These cancers are distinct from blood cancers (e.g., leukemia) and skin cancers, which are not covered by this initiative. By concentrating on these specific types of solid tumors, the Observatory aims to provide deeper insights into treatment pathways, medication use, and clinical outcomes across multiple healthcare settings.

Unlike traditional cancer registries, which often focus on limited data points or a specific patient group, the Solid Cancer Observatory offers a comprehensive, real-world view of cancer care. It integrates data from multiple sources, including clinical records, biomarker testing, and treatment outcomes, allowing for a deeper understanding of how therapies are applied in practice across different hospitals and regions. This dynamic, continuously updated approach enables ongoing, retrospective analysis of treatment patterns and patient journeys, providing insights that go beyond the static nature of typical cancer registries.

The incidence of biomarker testing in cancer is increasing, but it is still not uniformly applied across all cancer types or patient populations. The decision to perform biomarker testing is often influenced by several factors, including the type and stage of cancer, the availability of targeted treatments, and guidelines from clinical and medical societies. However, there is still a lack of consensus on the best criteria for when to use biomarker testing, especially for certain cancers. This gap in knowledge makes initiatives like the Solid Cancer Observatory particularly valuable, as they provide real-world insights into how biomarker testing is being used in practice, helping to refine decision-making criteria and improve the understanding of when and how biomarker testing can benefit patients.

To participate in the observatory or access the data collected, there are several options available:

1. Healthcare Providers: If you are a healthcare provider interested in gaining insights, you can join the observatory for free. This will allow you to access valuable data and trends specific to your institution.
2. Researchers: Researchers who are interested in studying solid cancers can request information from the observatory. This access will provide you with comprehensive data to support your research and help you gain deeper insights into the prevalence and impact of solid cancers.

3. Life Science Companies: Life science companies looking for detailed information can also request data from the observatory. This information can be crucial for developing new treatments, vaccines, and other healthcare solutions.

Patient Engagement

Optimise digital patient engagement activities while collecting valuable data.

Financial Analytics

Controlling costs and optimising operations through data-driven decision-making.

Blog

Solidifying Oncology Drug Effectiveness After Approval with Real-World Evidence

pexels-antoni-shkraba-5588323-1200x800-1

Customer Story

A Data-Driven Analysis of Care Pathways for Oncological Patients with Bone Metastases at HagaZiekenhuis

Stocksy_txp3c7f9c9dMmT300_Medium_2944384-edit (1)-1

Whitepaper

Join our Solid Cancer Observatory

Gain Unique International Pan-European Insights